dolutegravir and Alzheimer-Disease

dolutegravir has been researched along with Alzheimer-Disease* in 1 studies

Other Studies

1 other study(ies) available for dolutegravir and Alzheimer-Disease

ArticleYear
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
    Journal of medicinal chemistry, 2018, Aug-09, Volume: 61, Issue:15

    Contilisant, a permeable, antioxidant, and neuroprotectant agent, showing high nM affinity at H3R and excellent inhibition of the monoamine oxidases and cholinesterases, is an affine and selective S1R agonist in the nanomolar range, based on the binding affinity and functional experiment, a result confirmed by molecular modeling. In addition, contilisant significantly restores the cognitive deficit induced by Aβ

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterases; Histamine Antagonists; Indoles; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Piperidines; Protein Multimerization; Protein Structure, Quaternary; Receptors, Histamine; Receptors, sigma; Sigma-1 Receptor; Spatial Memory

2018